Drug-Induced Movement Disorder
Conditions
Brief summary
In this pilot study, the investigators will evaluate care delivery via telemedicine to individuals with drug-induced movement disorders (DIMDs). DIMDs can be disabling, and prevention is important; but these disorders are often under-reported, under-recognized and poorly managed. Interprofessional telemedicine for movement disorders is feasible and may provide similar care as in-person visits; however, the majority of studies to date have shown benefit in Parkinson's disease and further validation in other movement disorders is necessary. In this randomized controlled trial the aim is to study the acceptability, feasibility, and patient and clinician outcomes when a neurological consultation is provided for patients with DIMDs either in-person or through telemedicine. The investigators will apply the evaluation framework RE-AIM (Reach and Effectiveness, Adoption, Implementation, and Maintenance) to comprehensively assess the factors that may impact study success and program implementation. Mixed methods will be implemented to gather outcome data from mental health clinicians that refer patients and the patient participants.
Interventions
OTHERTelemedicine Consult
Neurological consultation completed remotely
OTHERIn-person Consult
Neurological consultation completed in-person
Sponsors
Neurocrine Biosciences
University of Vermont
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years or older * Willing and able to provide consent * Willing to have their Mental Health Clinician (MHC) share sensitive clinical information with the Neurology team * Able to travel to Neurology clinic * Have connectivity to Zoom using wi-fi or cellular data, either at home or a comfortable and private setting (such as MHC office)
Exclusion criteria
* Currently hospitalized * Neurologist determines patient requires care outside of the scope of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness; Client Satisfaction Questionnaire-8 (CSQ-8) | 12 months | How satisfied are patients with the program |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Effectiveness; PROMIS 29+2 V2.1 | 12 months | What are the impacts on patient health status |
| Effectiveness; referral forms and visit notes | 12 months | Was there concordance in diagnosis between the MHC and movement disorder specialist |
| Effectiveness; visit notes | 12 months | Was there an impact on care plan |
| Effectiveness; MHC survey and Qualitative Interviews | 12 months | Were the MHCs Satisfied with the program |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adoption | 12 months | Are there factors that determine whether a clinician will initiate participation in this program |
| Implementation | 12 months | What barriers exist that may determine the feasibility of the study and neurological consultation |
| Maintenance; MHC survey and qualitative interviews | 12 months | Could a telemedicine program similar to the one we develop for this study become a part of the routine organizational practices |
| Reach | 12 months | In this study, are we able to enroll a sample that is representative of the patient population that experiences DIMDs |
Countries
United States
Outcome results
None listed